The label for Kybella (deoxycholic acid injection, ATX-101) now carries warnings about unapproved use and persistent injection-site nodules, according to a report from Dermatology Advisor.

Kybella holds FDA approval for improving the appearance of moderate to severe submental fat — the so-called double chin — in adults. The label update draws prescriber attention to two distinct safety concerns: administration in anatomical areas outside the approved submental indication, and the occurrence of nodules at injection sites that persist beyond the expected treatment course.

The revision matters for dermatologists and aesthetic practitioners because Kybella's off-label use has expanded since the agent's approval, with clinicians injecting deoxycholic acid in regions such as the jowls, neck, and body contouring sites. The updated labeling language now flags that unapproved use carries risks the original label did not fully characterize.

Persistent nodules represent the second key addition. Transient swelling, bruising, pain, and numbness are well-documented, expected effects of chemical lipolysis with deoxycholic acid. Nodules that fail to resolve, however, pose a different clinical problem — one that may require extended follow-up, additional intervention, or patient counseling that differs from the standard post-treatment expectations clinicians typically communicate.

For practices, the label change carries practical implications beyond clinical management. Payers already distinguish on-label from off-label use in coverage determinations for injectable aesthetic agents, and a label that explicitly warns against unapproved use may sharpen that scrutiny. Practices that have built protocols around off-label Kybella administration should review their consent documentation to ensure it reflects the updated risk profile, including the possibility of durable nodules.

Patient counseling also shifts. Clinicians discussing Kybella with candidates for submental contouring should now address the nodule risk explicitly, set expectations about the timeframe in which nodules typically resolve, and outline the escalation path if they persist.

The update also lands in a competitive context. Deoxycholic acid injection competes with microfocused ultrasound, cryolipolysis, and surgical submentoplasty for submental fat, and an expanded warning on persistent adverse events could influence how clinicians weigh Kybella against energy-based alternatives in shared decision-making.

Practices that maintain Kybella in their aesthetic portfolios will want to monitor whether the label language prompts additional real-world safety data collection or postmarketing reports on nodule duration and off-label complications.